Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EML4 | Q9HC35 | 10/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 10/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | IKBKE | Q14164 | 5/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.42 |
| ▸ | RET | P07949 | 3/20 | 0.41 |
| ▸ | ROS1 | P08922 | 3/20 | 0.41 |
| ▸ | FLT3 | P36888 | 3/20 | 0.41 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL328289 | 0.91 | IKBKE (0.44) | EML4ALKCCR5IKBKETBK1 | |
| SCHEMBL10129612 | 0.84 | EML4 (0.65) | EML4ALKRETROS1FLT3 | |
| SCHEMBL17690612 | 0.82 | EML4 (0.47) | EML4ALKRETROS1FLT3 | |
| SCHEMBL17689742 | 0.80 | PARP1 (0.40) | EML4ALKIKBKETBK1FLT3 | |
| SCHEMBL10157702 | 0.79 | EML4 (0.54) | EML4ALKRETROS1FLT3 | |
| SCHEMBL10126816 | 0.76 | IKBKE (0.55) | EML4ALKIKBKETBK1RET | |
| SCHEMBL16206813 | 0.75 | EML4 (0.51) | EML4ALKRETROS1FLT3 | |
| SCHEMBL10155938 | 0.74 | PLAU (0.38) | EML4ALK | |
| SCHEMBL16206819 | 0.72 | ALK (0.47) | EML4ALKRETROS1FLT3 | |
| SCHEMBL16195799 | 0.72 | EGFR (0.61) | EML4ALKIKBKETBK1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | WATERS TECHNOLOGIES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | EML4 1/4885ALK 2/4885CCR5 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.